Medicines production

The British-Swedish company AstraZeneca, which has created a vaccine against coronavirus, plans to apply to the Ministry of Health of Russia to register its drug.

The Sputnik V vaccine seems to be more effective than other drugs against the Omicron strain. This was announced by Russian President Vladimir Putin on Wednesday.

On December 28, Russian President Vladimir Putin noted the high ability of the Russian Sputnik V coronavirus vaccine to fight the Omicron strain.

The head of the Turkish Ministry of Health has authorized the emergency use of the Turkish-made Turcovac coronavirus vaccine. This was announced on Wednesday, December 22.

Russia has not yet provided all the information necessary for the approval of the Russian Sputnik V coronavirus vaccine by the World Health Organization (WHO).

Research Center named after N.F. Gamalei is awaiting the arrival of a WHO delegation as part of the approval of the Russian Sputnik V coronavirus vaccine in January.

One of the developers of the AstraZeneca vaccine, professor Sarah Gilbert, warned that future pandemics could be more dangerous and more deadly than the coronavirus pandemic.

The concentration of the novel coronavirus vaccine for children aged six to 11 is likely to be 10 times less than the parent Sputnik V for adults.

The Russian Direct Investment Fund (RDIF) expects that more than 150 million Sputnik COVID-19 coronavirus vaccines will be produced at factories in China per year.

The effectiveness of vaccines against coronavirus will drop significantly due to the emergence of a new strain of "omicron", said Stefan Bansel, CEO of Moderna.

The American Chamber of Commerce in Russia (AmCham) has applied to the US State Department with a request to recognize the Sputnik V vaccination certificates.

400 children aged 12-17 years in Moscow were vaccinated against coronavirus as part of clinical trials of the Sputnik-M vaccine.

According to the expert, pets can be a source of coronavirus infection for their owners.

Two Russian vaccines, developed using genetic technologies on the principle of the Sputnik V vaccine, are undergoing preclinical trials today.

The effectiveness of the Russian Sputnik V coronavirus vaccine after vaccination of 1.2 million people in Belarus was 96.3%.